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Objective: the aim of this study is to investigate the clinical evolution, the spontaneous remission of the symp-
tomatology and the response to different treatments in a group of burning mouth syndrome patients.
Study Design: the sample was formed by a group of patients that were visited in the Unit of Oral Medicine of the 
Dentistry Clinic of the University of Barcelona, from the year 2000 to 2011. After revising the clinical records 
of all the patients that had been under control for a period of time of 18 months or longer, they were contacted by 
telephone. In the telephone interview, they were questioned about the symptomatology evolution and the response 
to the treatments received, noting down the data in a questionnaire previously performed. 
Results: the average duration of the symptoms was 6.5 years (+/-2.5 years). The most frequent treatments were: 
chlorhexidine mouthrinses, oral benzodiazepines, topical clonazepam, antiinflamatory drugs, antidepressants, 
antifungicals, vitamins, psycotherapy, salivary substitutes and topical corticoids.  The specialists that were con-
sulted with a higher frequency were: dermatologists (30%), othorrynolaringologists (10%) and psychiatrists (3%). 
In 41 patients the oral symptoms did not improve, 35 reported partial improvements, 12 patients worsened, and 
only in 3 patients the symptoms remitted. 
Conclusions: In three of the 91 patients studied the symptoms remitted spontaneously within the five years of 
treatment. Only 42% of the study population had improved the symptomatology significantly, and this improve-
ment would reach 60% if clonazepam were associated to psychotherapy.
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Introduction
Burning mouth syndrome (BMS), also named glossody-
nia, stomatodynia or stomatopyrosis, is a disease that, 
even though it has been described for many years, still 
entails problems when referring to diagnosis and treat-
ment (1-4). It is characterized by the presence of burn-
ing or stinging in any area of the oral mucosa, especially 
on the tongue and lips, with no type of lesion that could 
justify such symptoms.  This disease alters significantly 
the quality of life of the patients suffering from it (5). 
The profile of these patients is that of a postmenopausal 
woman, who would frequently suffer from anxiety and/
or depression. Nowadays, there is the debate whether 
the psychological alterations that they undergo are the 
cause or the consequence of this chronic pain. The pro-
file of these patients is particular: aged between 50 and 
60, they have been suffering aches for a long time, and 
have been visited and treated by different specialists, 
without obtaining any solution to their problem. It is 
usually accompanied by an important emotional profile 
and is often related to cancerofobia (6). Apart from the 
oral stinging, other sensitive alterations can take place: 
a feeling of dryness or gustative alterations – perception 
of bitter or metallic taste- (7). In some cases they also 
present other disestesias in the mouth, such as the feel-
ing of sand or swelling (7,8).
This disease has a high prevalence, which varies de-
pending on the studies from 0.7% to 15% (8). Never-
theless, on many occasions, these patients go from one 
specialist to another, with no answer to their problem. 
This unleashes a bigger anxiety, since they feel mis-
understood. As a matter of fact, there are many health 
practitioners, both in hospitals and private practices that 
do not provide a successful treatment for these patients, 
considering them as a burden, and being thankful every 
time they find another specialist interested in their man-
agement. The use of antidepressants, anxiolytics, hyp-
notics and other xerostomizing –such as antihyperten-
sive drugs and diuretics- may aggravate the feeling of 
dryness (9-14). People that suffer from this disease usu-
ally complain about the dry mouth. However, most of 
the studies that measure the saliva have not been able to 
demonstrate or prove quantitative alterations, although 
in some cases succeeded in proving qualitative altera-
tions (9,14,15).
Although there are many studies published in the litera-
ture, the true aetiopathogeny of this disease still remains 
unknown, which hinders the advancement of the inves-
tigation of a treatment that totally effective (10,11,13,16). 
Some authors treat these symptoms with capsaicin (17), 
some others with acid alpha-lipoic (alone or associated 
to gabapentin) (18,19), with antidepressants or benzo-
diacepines, such as clonazepam (7,20-22). The clinical 
evolution of this disease is usually chronic, alternating 
periods of exacerbation of the symptomatology and pe-
riods of improvement. In some cases, spontaneous re-
missions have been described (23).
Based on the hypothesis that in a small percentage of 
patients the symptoms return spontaneously 5 years 
from the beginning, we consider performing a study 
with the objective of investigating the clinical evolu-
tion, the spontaneous remission of the symptoms and 
the response to different treatments, in a group of pa-
tients with BMS.
Material and Methods
Sample: All the patients visiting the Oral Health Unit of 
the Odontology faculty of the University of Barcelona 
from January 2000 to May 2011 were examined meticu-
lously with the objective of ruling out other underlying 
diseases. It was measured the saliva flow and performed 
a blood analysis in order to evaluate complete blood cell 
counts, blood glucose levels, serum iron and transferrin 
levels, serum vitamin B 12 and folate levels. It was also 
performed a mycological culturing with the aim of rul-
ing out oral candidiasis. In the cases where it was sus-
pected an allergy related to the contact with any materi-
al of the dental prosthesis, “pach tests” were requested. 
The clinical history of all patients was also reviewed. 
A total of 184 medical records were revised, and only 
the records of the patients with BMS of over 18 months 
of evolution were selected to be part of the study. In 
the medical record of the patients, all the data obtained 
from the oral exploration and the blood test was regis-
tered. It was also registered the pathologic background 
of the patient, drugs taken, the clinical characteristics 
of the stinging, the time of evolution, the different treat-
ments received, and the clinical response.
Out of the 184 revised medical records, only 91 patients 
were considered for the study –with a time evolution 
of over 18 months-. Were excluded from the study 65 
patients with less than 18 months evolution, 13 patients 
which did not attend to the controls and 5 patients that 
were not located. These 91 patients were interviewed by 
telephone in order to obtain information in relation to 
their illness and the treatments received.
Methods: in order to register the answers from the tele-
phone interviews, a questionnaire was designed (Table 
1). In this document, all the information referring to the 
prescribed treatments (either by our group, by any other 
professionals, or by self-prescriptions) was registered, 
as well as the evolution of the symptoms, especially the 
stinging, as a result of the different treatments. 
Results
Out of the 91 patients suffering from BMS of >18 
months of evolution, 85 were women and 6 were men. 
The average age was 69.9 years (from 40 to 85 years). 
The average duration of the symptoms was 6.5 years 
(+/-2.5 years), and the time during which the patients 
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were managed was 18 to 94 months (7.83 years), with 
the average at 54 months. The clinical characteristics 
are summarized in figure 1. Furthermore, the outstand-
ing statistics show that 87 (97.8%) of the patients ex-
perienced stinging on the tongue and 41 (45%) on the 
lip, with a marked preponderance on the lower lip (39 
of the 41).  
-Therapies
Common treatments used by patients with oral burn-
ing symptoms include mouth wash of chlorhexidine, 
oral benzodiazepines, topical clonazepam, mouth wash, 
topical corticoids, psychotherapy, salivary substitutes, 
vitamins, anti-fungicals, and other treatments such as 
anti-inflammatory drugs or anti-depressants. 32 pa-
tients (35% of the sample) had already started some 
sort of treatment, but they quit after a few days with-
out improvements. The summary of treatments consid-
ered in our analysis is listed in figure 2. As shown, the 
most common treatments were: oral benzodiazepines 
(36.3%), topical clonazepam (37.4%), antifungicals 
(21.9%), mouth wash (56.1%) and others such as anti-
Table 1. Registration form.
Please tell us all treatments tested for SBA
1-benzodiazepines      4- antifungals 7- topical corticoids 10-vitamins                
2-topical benzodiazepines 5-anti-inflammatory agents 8-psycotherapy            11-others (specify)     
3-antidepressants           6-mouthrinse                9-salivary substitutes 12-none
Please, indicate which of the following specialists you have 
visited for BMS.
1-general dentists 4-homeopaths
2-psychologists            5-others  (specify)             
3- neurologists         6-none     
Are you currently using any of the following treatments? If the answer is yes, please indicate which. 
1- benzodiazepines      4- antifungals 7- topical corticoids 10-vitamins                
2-topical benzodiazepines 5- anti-inflammatory agents 8- psycotherapy            11-others (specify)     
3- antidepressants           6- mouthrinse                9-salivary substitutes 12-none
Have any of the following drugs or treaments provided you 
with any relief from discomfort. 
1-no, symptoms remain the same
2-no, symptoms have worsened
3-yes, symptoms have improved partially
4-yes, symptoms have completely disappeared
Please indicate the areas of discomfort
1-lips 2-orofaringe 3-gingiva 4-palate
5-tongue 6-others (specify) 7-multiple areas
inflammatory and anti-depressants (23.08%). The sum-
mary of the evolution of patients using these five treat-
ments either on its own or in conjunction with other 
treatments is listed in table 2. In addition, pair-wise cor-
relations between types of evolution for each of these 
five treatments are listed in table 3. Moreover, the sum-
mary of the evolution of patients using different combi-
nations of these common treatments is listed in table 4. 
As shown, 37% (34 out of 91) of the patients used topical 
clonazepam and 24% of these patients felt an improve-
ment in their condition. This represents the 62% of pa-
tients improving their condition. That is, more than a 
half of patients improving their condition used topical 
clonazepam in their treatment. Main improvements are 
in patients using topical clonazepam on its own (22,8%) 
and topical clonazepam combined with mouthwashes 
(28.6%) as listed in table 4. As listed, treatments consid-
ering only mouthwash led to no improvement in patient’s 
condition. However, the combination of mouthwashes 
with topical clonazepam resulted in an improvement 
on more than 26 patients. Furthermore, only 12.1% and 
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Fig. 1. Data referring to the clínical situation of the patients. (*) It refers to the total for each of the clinical behav-
iours. Bear in mind that every patient is usually under more than one treatment at any one time. 
Fig. 2. Correlation between symptomatology and the medication used. (*) It refers to the total for each of the clinical 
behaviours. Bear in mind that every patient is usually under more than one treatment at any one time. 
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pines    
21,9% 48.8% 7,7% 20.0% 6,6% 50.0% 36,3%
Topical clon-
azepam
12,1% 26.8% 24,2% 62.9% 1,1% 8.3% 37,4%
Antifungals 10,1% 24.4% 6,6% 17.1% 4,4% 33.3% 21,9%
Mouth wash 32,9% 73,2% 26,5% 42,9% 6,6% 50,0% 56,1%
Others 16,5% 36,6% 2,2% 5,7% 4,4% 33,3% 23,1%
Table 2. Degree of occurrence for the most common treatments. Statistics include the percentage over the dataset (i.e., ‘unchanged over all 
patients’ is the percentage of unchanged patients over the total number of patients) and also over the patients with a specific evolution (i.e., 
‘unchanged over unchanged’ refers to the percentage of unchanged patients using an specific treatment over the total number of unchanged 







Benzodiazepines    C -0.15 -0.14 -0.07
P 0.14 0.18 0.47
Topical clonazepam C -0.21 -0.04 -0.06
P 0.04 0.71 0.57
Antifungals C -0.09 -0.07 -0.06
P 0.38 0.47 0.59
Mouth wash    C -0.031 -0.18 -0.12
P 0.00 0.07 0.26
Others   C -0.07 -0.09 -0.03
P 0.53 0.37 0.76
Table 3. Degree of correlation between the most common treatments independent of the combinations. C 
stands for pairwise correlation coefficient and P stands for Pearson coefficient. There is a significant correlation 
between two populations if P<0.5.
1.1% of the patients felt no improvement (unchanged) 
or deterioration (worsening) respectively when topical 
clonazepam was included in their treatment. Moreover, 
there is not significant correlation between pairwise 
comparisons of patient’s evolution using treatments in-
cluding topical clonazepam (table 3). Hence, from these 
results, we can conclude that including topical clon-
azepam improves the condition of a patient presenting 
oral burning symptoms. 
Similarly, 36.3% (33 out of 91) of the patients used oral 
benzodiazepines in their treatments (Table 2). However, 
only 7.7% of them felt an improvement in their condition. 
In this case, most of the patients felt no changes (21.9%) 
or worsening (6.6%). This represents the 48.8% of pa-
tients feeling no changes and 50.0% of patients feeling 
worse, respectively. In addition, treatments considering 
only oral benzodiazepines resulted in worse symptoms 
in 25% of the patients (Table 3). Furthermore, there is 
not significant correlation between comparisons of pa-
tient’s evolutions when including oral benzodiazepines. 
Hence, from these results, we can conclude that the use 
of oral benzodiazepines does not improve the condition 
of patients presenting oral burning symptoms.     
-Other specialities
74 of the patients visited different specialists (i.e., der-
matologists (30%), othorhinolaryngologist (10%), psy-
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Benzodiazepines 3.3% 7.3% 2.2% 5.7% 3.3% 25.0% 8.8%
Topical clonazepam 0% 0% 8.8% 22.8% 0% 0% 8.8%
Benzodiazepines  -Topical clonazepam 1.1% 2.4% 2.2% 5.7% 0% 0% 3.3%
Benzodiazepines  - Antifungals 1.1% 2.4% 0% 0% 0% 0% 1.1%
Others 0% 0% 1.1% 2.9% 0% 0% 1.1%
Benzodiazepines  - Others 1.1% 2.4% 0% 0% 1.1% 8.3% 2.2%
Topical clonazepam- Others 1.1% 2.4% 0% 0% 0% 0% 1.1%
Benzodiazepines – Topical clonazepam - 
Others
0% 0% 1.1% 2.9% 0% 0% 1.1%
Antifungals - Others 1.1% 2.4% 0% 0% 1.1% 8.3% 2.2%
Benzodiazepines  - Antifungals - Others 1.1% 2.4% 0% 0% 0% 0% 1.1%
Benzodiazepines  - Topical clonazepam - 
Antifungals –  Others
1.1% 2.4% 0% 0% 0% 0% 1.1%
Mouthwashes 12.1% 26.8% 1.1% 2.8% 2.2% 16.7% 15.4%
Benzodiazepines  - Mouthwashes 2.2% 4.9% 2.2% 5.7% 1.1% 8.3% 5.5%
Topical clonazepam - Mouthwashes 1.1% 2.4% 11.0% 28.6% 0% 0% 12.1%
Benzodiazepines  -Topical clonazepam  - 
Mouthwashes        
4.4% 9.8% 0% 0% 0% 0% 4.4%
Antifungals –  Mouthwashes        1.1% 2.4% 1.1% 2.9% 1.1% 8.3% 3.3%
Benzodiazepines -Antifungals  - Mouth-
washes        
1.1% 2.4% 0% 0% 0% 0% 1.1%
Topical clonazepam –Antifungals - 
Mouthwashes        
0% 0% 1.1% 2.9% 0% 0% 1.1%
Mouth washes - Others 4.4% 9.7% 0% 0% 1.1% 8.3% 5.5%
Benzodiazepines  - Mouthwashes  - 
Others
3.3% 7.3% 0% 0% 0% 0% 3.3%
Topical clonazepam  - Mouthwashes - 
Others
1.1% 2.4% 0% 0% 0% 0% 1.1%
Benzodiazepines -Topical clonazepam -  
Mouthwashes  - Others
2.2% 4.9% 0% 0% 1.1% 8.3% 3.3%
Table 4. Degree of occurrence for different treatment combinations of the most common treatments. See table 2 for details.
chiatrists (3%), psychologists (2%), neurologists (2%), 
homeopaths (1%) and rheumatologists (0.5%)) for al-
ternative oral burning treatments. In particular, 45 pa-
tients (49.45%) visited more than one specialist and 13 
patients (14.25%) visited up to four specialists. Finally, 
16 of these patients visited other dentists. 
-Evaluation of the stinging
As shown in figure 2, in 41 patients (48%) the oral 
symptoms did not improve, 35 (38%) referred partial 
improvements, 12 (13%) worsened and in only 3 pa-
tients (3.2%) the symptoms remitted spontaneously. 
For the most part, these patients had been under dif-
ferent therapies which had been withdrawn due to the 
little success they experienced. These 3 patients were 
women. In one of them, the symptoms disappeared af-
ter an 18-month evolution, for unknown reasons. In the 
other two, symptoms disappeared when the associated 
anxiety unleashed by family issues was resolved, one 
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of them after 20 months of evolution and the other after 
22 months. The 41 patients that had not improved had 
consulted with an average of 4 professionals, compared 
to the average of 2 professionals that the 91 patients vis-
ited. Out of the 41 patients that did not display any im-
provement, 12 (13%) had used topical clonazepam with 
or without other treatments, while 21 of the 35 patients 
that did show improvements had used it, resulting in a 
statistical significance (p<0,00). Of the 12 patients that 
worsened, one of them had used, among other treat-
ments, topical clonazepam.
Discussion
Although BMS aetipathology mechanisms still remain 
unknown, it seems pretty obvious that BMS disease is 
closely related to psychological alterations. Neverthe-
less, it has not yet been scientifically proven. Recent in-
vestigations have related this disease with neurological 
alterations in the somatosensory branch of the Trigemi-
nal Nerve (24).  In that work, the authors suggest that the 
alterations in the peripheral nervous system, especially 
in the sensitive branch of the Trigeminal, having found 
out these alterations in the pupil reflex (25). Other recent 
studies report improvements in BMS symptoms using 
acid alpha-lipoic acting as a neuroprotector (18,19), or 
using topical clonazepam, a drug of neurotropic action 
(20). Or even clonazepam binding topic in systemic 
(26). These results reinforce the promising hypothesis 
that the aetiopathogeny of the BMS intercedes in a pe-
ripheral neurological alteration. There are several stud-
ies analyzing the effects of different BMS treatments 
(10,11,13,17). However, currently, there is no completely 
effective treatment for BMS.  
Gruskha et al. (27) in a review presented in 1991 re-
vised the clinical course of 43 patients affected by BMS 
during a period of time of approximately 6 years. After 
completing a telephone interview, 23 reported they had 
not felt any changes. 13 reported complete healing and 7 
reported a partial improvement in all the symptoms. Out 
of the 13 patients that presented a total remission in the 
symptoms, 9 were spontaneous, and did not require any 
kind of treatment, corresponding to 20% of the patients. 
In our population group, 48% of the patients did not 
experience any improvement, this number is similar to 
the data presented by Grushka et al (27). In their study, 
54% of the patients reported not feeling any changes in 
the clinical evolution. In our group, we found a higher 
number of patients with a partial improvement and a 
lower number with total remission. Only 3 patients ex-
perienced complete remission of the symptomatology.
In another study regarding the clinical characteristics of 
the BMS, Danhauer et al. (28) recounted the spontane-
ous remission of the symptoms in 1 of the 26 patients 
(3.8%). The study population comprises of 26 patients 
with the average age being 59.08 years, +/-12.4 years, 
and the average duration of the symptoms 2.27 years 
+/- 3.81 years. We have found spontaneous remission in 
3 of 91 patients (3.2%).
More recently, in 2006, Sardella et al. (23),  published 
a study with 53 BMS patients (48 women and 5 men) 
with an age range from 33 to 82 years (average age of 
67.7 years). The average duration of the symptoms was 
5.5 years+/- 1.9 years and the average follow-up period 
was 56 months. As a direct consequence of different 
fulfilled treatments, 26 patients (49%) did not notice 
any change in oral symptoms. 15 patients (28.3%) re-
lated some sort of improvement and 10 patients (18.9%) 
reported worsening of their comfort. Symptoms disap-
peared spontaneously in only 2 patients (3.7%), with no 
given treatment. In our study, 41 patients did not im-
prove, 35 reported partial improvements, 12 worsened 
and 3 showed spontaneous remission of their symp-
tomatology. Although our results are similar to those 
from Sardella et al., (23) our study reflects a higher 
number of patients with partial improvements. 
Our analysis confirms that more than 58% of the pa-
tients are in never-ending struggles to find drugs to alle-
viate their symptoms. Moreover, these patients are great 
consumers of the sanitary resources. These numbers 
could exceed 75%, since the improvements reported are 
only partial.
In this study, we have analyzed a group of 91 patients 
suffering BMS symptoms. From the results of our 
analysis, we can conclude that for a small number of 
patients, symptoms can remit spontaneously, within 5 
years after the onset of BMS. Furthermore, only partial 
improvements were achieved in 38,4% of the patients 
having different treatments (e.g., topical clonazepam 
and mouth washes). This improvement is higher (up 
to 61,7%) when patients include topical clonazepam in 
their treatment. Nevertheless, in most cases, these im-
provements are closely related to psychotherapy.
It should be considered that the sample of patients in 
our study is not particularly large and that the time they 
were subject to controls was more than 18 months but not 
achieving, in some instances, the 5 years that the patients 
are subject to controls in other studies. Therefore the dif-
ferences in the results may result from the smaller control 
time of the clinical evolution. We believe it is necessary 
to continue investigating this matter with larger popula-
tions and with controls during longer periods.
It is also necessary to carry on the investigation of the 
aetiopatogeny mechanisms of this disease to find a cur-
ative treatment.
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